Published August 26, 2016 | Version v1
Journal article

Prevalence, risk factors for infection and subtype distribution of the intestinal parasite Blastocystis sp. from a large-scale multi-center study in France

Others:
Centre d'Infection et d'Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 (CIIL) ; Institut Pasteur de Lille ; Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre National de la Recherche Scientifique (CNRS)
Laboratoire Microorganismes : Génome et Environnement (LMGE) ; Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Université d'Auvergne - Clermont-Ferrand I (UdA)-Centre National de la Recherche Scientifique (CNRS)
CHU Gabriel Montpied [Clermont-Ferrand] ; CHU Clermont-Ferrand
CHU Clermont-Ferrand
Maladies infectieuses et vecteurs : écologie, génétique, évolution et contrôle (MIVEGEC) ; Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD [France-Sud])
Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)
Hôpital Henri Mondor ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)
Institut de Parasitologie et de Pathologie Tropicale (IPPTS) ; Université de Strasbourg (UNISTRA)
Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)
Centre d'Etude des Pathologies Respiratoires (CEPR), UMR 1100 (CEPR) ; Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Université Montpellier 1 - UFR de Médecine (UM1 Médecine) ; Université Montpellier 1 (UM1)
Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)
Cibles et médicaments de l'infection, de l'immunité et du cancer (IICiMed) ; Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques ; Université de Nantes (UN)-Université de Nantes (UN)
Centre méditerranéen de médecine moléculaire (C3M) ; Université Nice Sophia Antipolis (1965 - 2019) (UNS) ; COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA)
Hospices Civils de Lyon (HCL)
This work was supported by grants from the Programme Orientations Stratégiques from the University of Lille 2, the Fonds Hospitalier d'Aide à l'Emergence from the CHRU of Lille, the Centre National de la Recherche Scientifique and the Institut Pasteur of Lille. DES was supported by a PhD fellowship from the Conseil National de la Recherche Scientifique and the AZM & Saade Association and AC by a PhD fellowship from the University of Lille 2 and the Institut Pasteur of Lille.

Description

Blastocystis sp. is the most common intestinal parasite of humans. Despite its potential public health impact, epidemiological data regarding the prevalence and molecular subtype distribution of Blastocystis sp. in Europe are rarely reported. Therefore, the first multi-center epidemiological survey performed in Europe was conducted in France to diagnose and subtype Blastocystis sp. and to identify risk factors for infection. Stool samples from 788 patients were collected either in summer or winter in 11 hospitals throughout France together with patient data. All stool samples were tested for the presence of Blastocystis sp. by quantitative PCR targeting the SSU rDNA gene. Positive samples were sequenced to determine the distribution of the subtypes in our cohort. Statistical analyses were performed to identify potential risk factors for infection. Using quantitative PCR, the overall prevalence of Blastocystis sp. was shown to reach 18.1 %. The prevalence was significantly higher in summer (23.2 %) than in winter (13.7 %). Travellers or subjects infected with other enteric parasites were significantly more infected by Blastocystis sp. than non-travellers or subjects free of other enteric parasites, respectively. Different age-related epidemiological patterns were also highlighted from our data. The prevalence of Blastocystis sp. was not significantly higher in patients with digestive symptoms or diagnosed with chronic bowel diseases. Among symptomatic patients, Blastocystis sp. infection was significantly associated with abdominal pain. Gender, socioeconomic status, and immune status were not identified as potential risk factors associated with infection. Among a total of 141 subtyped isolates, subtype 3 was predominant (43.3 %), followed by subtype 1 and subtype 4 (20 %), subtype 2 (12.8 %), subtype 6 and subtype 7 (2.1 %). No association between ST and clinical symptoms was statistically evidenced. A high prevalence of Blastocystis sp. infection was found in our French patient population. Seasonal impact on the prevalence of Blastocystis sp. was highlighted and recent travels and age were identified as main risk factors for infection. Most cases were caused by subtypes 1 to 4, with a predominance of subtype 3. Large variations in both prevalence and ST distribution between hospitals were also observed, suggesting distinct reservoirs and transmission sources of the parasite.

Abstract

International audience

Additional details

Created:
December 4, 2022
Modified:
December 1, 2023